Novanta to Acquire Riverpoint Medical, Expanding Medical Portfolio
NOVT sits 67% above its 52-week low of $98.27.
Summary
Novanta Inc. announced its acquisition of Riverpoint Medical, a strategic move to expand its product portfolio. This follows the company securing $200 million in new delayed draw term loan commitments on May 15th, which could provide financing for this transaction. The acquisition is expected to enhance Novanta's presence in the medical sector and contribute to future growth.
At the time of this announcement, NOVT was trading at $164.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $98.27 to $171.85. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.